In this review:
This publication is intended as an educational resource for healthcare professionals, particularly those who may encounter hidradenitis suppurativa/acne inversa (HS) in an acute setting. It aims to assist with recognition of the disease, and reviews the available treatments, both pharmacological and surgical. Particular emphasis is given to adalimumab, the only pharmacological treatment with registered approval for HS, both in New Zealand and worldwide.
Download PDF